Open Access

Bone marrow ectopic expression of a non-coding RNA in childhood T-cell acute lymphoblastic leukemia with a novel t(2;11)(q11.2;p15.1) translocation

  • Maria Corsignano Guastadisegni1,
  • Angelo Lonoce1,
  • Luciana Impera1,
  • Francesco Albano2,
  • Pietro D'Addabbo1,
  • Sebastiano Caruso3,
  • Isabella Vasta4,
  • Ioannis Panagopoulos5,
  • Anna Leszl6,
  • Giuseppe Basso6,
  • Mariano Rocchi1 and
  • Clelia Tiziana Storlazzi1Email author
Contributed equally
Molecular Cancer20087:80

https://doi.org/10.1186/1476-4598-7-80

Received: 19 September 2008

Accepted: 23 October 2008

Published: 23 October 2008

Abstract

Chromosomal translocations play a crucial role in tumorigenesis, often resulting in the formation of chimeric genes or in gene deregulation through position effects. T-cell acute lymphoblastic leukemia (T-ALL) is associated with a large number of such rearrangements. We report the ectopic expression of the 3' portion of EST DA926692 in the bone marrow of a childhood T-ALL case showing a t(2;11)(q11.2;p15.1) translocation as the sole chromosome abnormality. The breakpoints, defined at the sequence level, mapped within HPS5 (Hermansky Pudlak syndrome 5) intron 1 at 11p15.1, and DA926692 exon 2 at 2q11.2. The translocation was accompanied by a submicroscopic inversion that brought the two genes into the same transcriptional orientation. No chimeric trancript was detected. Interestingly, Real-Time Quantitative (RQ)-PCR detected, in the patient's bone marrow, expression of a 173 bp product corresponding to the 3' portion of DA926692. Samples from four T-ALL cases with a normal karyotype and normal bone marrow used as controls were negative. It might be speculated that the juxtaposition of this genomic segment to the CpG island located upstream HPS5 activated DA92669 expression. RQ-PCR analysis showed expression positivity in 6 of 23 human tissues examined. Bioinformatic analysis excluded that this small non-coding RNA is a precursor of micro-RNA, although it is conceivable that it has a different, yet unknown, functional role. To the best of our knowledge, this is the first report, in cancer, of the activation of a small non-coding RNA as a result of a chromosomal translocation.

Findings

Acquired balanced chromosomal translocations provide crucial diagnostic and prognostic data in cancer patients. They are probably pathogenetically significant as initiating events if present as the only cytogenetic changes [1]. These rearrangements often result in the formation of a fusion gene, encoding a chimeric oncogenic protein, or in the deregulation of the expression pattern of genes flanking the breakpoint regions by promoter swapping [13]. Overall, gene deregulation can be accomplished through position effects, such as a gene juxtaposition close to an active chromatin domain. More rarely, translocations may result in gene downregulation because of hypermethylation of CpG islands at the breakpoint [4], or in the formation of chimeric transcripts that do not encode for a protein with oncogenic potential [5].

T-ALL, as other hematological malignancies, is associated with a number of chromosomal abnormalities, resulting either in a position effect or in a gene fusion [6].

Here we report the cloning of a novel balanced t(2;11)(q11.2;p15.1) translocation, found as the sole cytogenetic abnormality in the BM of a childhood T-ALL case, accompanied by the ectopic expression of the 3' portion of EST DA926692.

A 14-year-old male patient was referred to our hospital for rhinolalia. Total body CT disclosed a diffuse enlargement of the rhinopharynx vault, lymphoid hyperplasia of the Waldeyer's tonsillar ring, and a mediastinal enlargement. BM aspiration showed 90% of blast cells. Flow cytometry revealed that blast cell population was positive for CD 45, 2, 5, 7, and cytoplasmic CD3, while negative for CD1a and surface CD3. These findings were consistent with a diagnosis of early T-ALL, thus the patient started treatment based on AIEOP-BFM ALL 2000 protocol [7].

At the end of induction therapy, the patient was categorized as "high risk" due to incomplete remission, as per protocol stratification criteria. After consolidation therapy, the BM aspirate showed no haematological remission, so treatment continued following the AIEOP LLA REC 2003 protocol and complete hematological remission was obtained.

One year from diagnosis, the patient underwent HLA-identical hematopoietic stem cell transplantation from an unrelated donor. He is now doing well and is still in hematologic remission.

G-banding analysis of bone marrow metaphases at onset revealed the karyotype 46,XY,t(2;11)(q11.2;p15.1) [27] [8] (Fig. 1A). FISH analysis excluded the presence of known rearrangements (data not shown), and revealed that the chromosome 11 breakpoint was encompassed by the BAC clone RP11-320K10 (chr11:18,229,291–18,413,758) and the fosmid G248P8335B2 (Fig. 1B), harboring the 5' UTR regions of two genes, HPS5 and GTF2H1, located 422 bp apart and in opposite transcriptional orientation (Fig. 1F).
Figure 1

Results of the cytogenetic and genomic characterization of the t(2;11) traslocation breakpoints: A) Karyotype of the case described in the present study. The black arrows point on derivative chromosomes 2 and 11. B) FISH results obtained with fosmids and BAC clones delimiting the breakpoint regions on der(2) and der(11). C) Map of chromosome 2 breakpoint region, according to the latest release of the UCSC Genome Browser (March 2006), delimited by BAC clones RP11-1141J14 (left) and RP11-716G6 (right). RefSeq Genes and CpG islands are represented in blue and green, respectively. Intra-chromosomal duplications are reported at the bottom of the figure. Gray, yellow and orange colours refer to the percentage of sequence similarity of the duplication (respectively 90–98%, 98–99%, and >99%). D) FISH results obtained using the Chr2-97-1 Long-PCR product on the bone marrow of the patient. E) Detailed magnified map of the chromosome 2 breakpoint region, showing the location of the Chr2-97-1 probe. F) Map of the breakpoint region on chromosome 11. G) and H) Partial chromatograms of the junctions sequences on both derivative chromosomes 11 (G) and 2 (H). Inserted nucleotides [three (CAT) and sixteen (GGCGGTATGTCCGTAC) at der(11) and der(2), respectively] at the junctions are underlined in purple.

The break on chromosome 2 was mapped within the interval chr2:96,884,868–97,812,993, delimited by the BACs RP11-1141J14 (chr2:96,884,868–97,038,565) and RP11-716G6 (chr2:97,631,541–97,812,993) at 2q11.2, yielding FISH signals on der(2) and der(11), respectively (Figs. 1B,C). It was not possible to further refine this breakpoint region by large-insert probes, as it is almost entirely composed of segmental duplications. We identified two small regions devoid of duplicons: chr2:97,284,347–97,296,849 (12,503 bp) and chr2:97,379,383–97,391,787 (12,405 bp) (Figure 1E). We obtained a long-range PCR product from the latter interval, that appeared to encompass the breakpoint on chromosome 2 (Figure 1D,E). This conclusion, however, was regarded with caution, since the region is rich in copy number variants (UCSC, Structural Variation track) providing a possible alternative explanation for the FISH results. The amplified interval does not contain known genes, although a number of ESTs of unknown function are annotated (Fig. 1E).

Vectorette-PCR using a reverse primer (hpsgtf-R, Table 1), specific for the genomic segment between genes HPS5 and GTF2H1, produced a fragment of approximately 800 bp. The sequence (Accession No. EU617360) showed that chromosome 11 at nt 18,300,006 (HPS5 intron 1) was fused with chromosome 2 at nt 97,384,504 (EST DA926692 exon 2) (Fig. 1G). Unexpectedly, sequences from chromosomes 2 and 11 had the same orientation.
Table 1

Primers for PCR and sequencing.

Designationa

Sequence (5'->3')

Positionb

Gene

chr2-97-1F

AGCCTGTGGTGTGTGTATGAAC

chr2:97,380,441–97,380,462

-

chr2-97-1R

TGAGTGTAGGTGACTGGTGAGG

chr2: 97,391,465–97,391,486

-

hpsgtf-R

TGACACCTTCCGCTAGTTCC

chr11:18,300,606–18,300,625

-

Hps5-F

CCTCCCTGCTTCTTTTTCCA

chr11:18,299,339–18,299,358

HPS5

HPS5ex20-3216Fc

TGCAGGTCTTGTGGTTTCTG

chr11:18,263,475

HPS5

HPS5ex21-3255Rc

TCTTCTCTCCAGCTCCAAACA

chr11:18,261,979–18,261,999

HPS

HPS5ex1-19Fc

TTCACGTTCCGCTCTTAGTG

chr11:18,300,260–18,300,279

HPS5

HPS5ex1-96Rc

CACATCCAGGGCAGTACCTC

chr11:18,300,183–18,300,202

HPS5

HPS5ex1-181F

TGGTTACTGGGTCTCCTCTCA

chr11:18,300,107–18,300,127

HPS5

HPS5-intr1-F

TGTGTTTTGTTCATCCCTGTG

chr11:18,300,006–18,300,026

HPS5

DA926692 ex1Fc

TCAGTCCCAGTCAGGACACA

chr2:97,384,972–97,384,991

DA926692

DA926692 ex1Rc

AGAGCCAGAGCAGCAGGAG

chr2:97,384,918–97,384,936

DA926692

DA926692 ex2aF

CCATCAAGGGAAGCAGATGT

chr2:97,384,457–97,384,476

DA926692

DA926692 ex2aR

GAGGCACCAGGAGAAGCAT

chr2:97,384,418–97,384,436

DA926692

DA926692ex2anewFc

CCCACAGTGTTACAAGTCATAACATA

chr2:97,384,479–97,384,504

DA926692

DA926692ex2anewRc

AGGAAGCTTCATGGCTCCTT

chr2:97,384,334–97,384,353

DA926692

Beta-act Fc

CTGGAACGGTGAAGGTGACA

chr7:5,533,739–5,533,758

ACTB

Beta-act Rc

AAGGGACTTCCTGTAACAACGCA

chr7:5,533,619–5,533,641

ACTB

CD110063-R

CACCAGGAGGCAGACGAG

chr2:97,391,951–97,391,968

CD110063

ACTB-F

GGCATCGTGATGGACTCCG

chr7:5,534,773–5,534,789

ACTB

ACTB-R

GCTGGAAGGTGGACAGCGA

chr7:5,533,972–5,533,990

ACTB

GTF2H1ex9-1201F

AGCAGTCAAAAGGGCGAAAT

chr11:18,326,030–18,326,043/18,330,004–18,330,010

GTF2H1

GTF2H1ex10-1272R

TTCTTGAGGTTTAGTGCAATCG

chr11:18,330,062–18,330,083

GTF2H1

ANKex2-351F

CCAACCGGAAATGGTACATC

chr2:97,147,558–97,147,577

ANKRD36

ANKex2-451R

AGAGTTGCACAAGCCTCCTG

chr2:97,147,823–97,147,842

ANKRD36

FAHD2Bex5-829F

TGTAGCAGATCCACACAACTTAAA

chr2:97,113,730–97,113,742/97,115,163–97,115,171

FAHD2B

FAHD2Bex6-864R

GACGACTTCCCCATTCACTC

chr2:97,113,695–97,113,714

FAHD2B

KIAA1641ex2-214F

AGAAAATGGGATGCAGGATT

chr2:97,492,508–97,492,527

KIAA1641

KIAA1641ex2-245R

GAAATTGACTTCTCATCTGGTCTAA

chr2:97,490,960–97,490,957/chr2:97,492,476–97,492,496

KIAA1641

ZAP70ex11-1678F

AGCTACTACACTGCCCGCTCA

chr2:97,720,549–97,720,560/97,720,651–97,720,660

ZAP70

ZAP70ex11-1749R

CTGCGGCTGGAGAACTTG

chr2:97,720,709–97,720,726

ZAP70

a F denotes forward; R denotes reverse;

b Position, at nucleotide level, according to the UCSC database, using the BLAT tool http://genome.ucsc.edu/cgi-bin/hgBlat;

cPrimer used in Real-Time PCR analysis.

The same approach was used to clone the reciprocal genomic fusion DA926692/HPS5. Vectorette PCR with a forward primer (hps5-F, Table 1) designed within HPS5 intron 1 yielded a fragment of 1,050 bp. The sequence (Accession No. EU617359) revealed that chromosome 2, at nt 97,384,507 (DA926692 exon 2), was fused with chromosome 11 at nt 18,299,998 (HPS5 intron 1) (Fig. 1H). Again, sequences from the two chromosomes had the same orientation. These observations clearly suggested that one of the two sequences had undergone a submicroscopic inversion before translocation. As a consequence, DA926692 and HPS5 were brought, by the inversion, into the same orientation.

5'- and 3'-RACE-PCR as well as RT-PCR experiments, aimed at cloning possible HPS5/DA926692 chimeric transcripts, failed.

Further RQ-PCR analyses aiming at quantifying the expression levels of genes flanking the breakpoints, i.e. HPS5 (Fig. 2A) and GTF2H1 (data not shown) on chromosome 11, and ANKRD36, FAHD2B, KIAA1641, ZAP70 on chromosome 2, revealed no misexpression in the present case compared to other T-ALL cases without the t(2;11) translocation (data not shown).
Figure 2

Results of the HPS5 and DA926692 gene expression analysis: A) and B) RQ-PCR analyses of HPS5, and DA926692 exon1, respectively, in the present case [t(2;11), four control childhood T-ALL samples [immunophenotype: early (#1,2), thymic (#3), and mature (#4) T-ALL], the mean Ct value of the controls (mean), normal BM and PB. A) The results showed no statistically significant change in HPS5 expression level with primers for exon1 (HPS5ex1-19F+HPS5ex1-96R) and exons 20-21 (HPS5ex20-3216F and HPS5ex21-3255R), if compared with the mean Ct value of the childhood T-ALL controls. B) The results showed comparable DA926692 transcriptional levels, when evaluated with exon 1 primers (DA926692ex2F and DA926692ex2R), between the patient with t(2;11) and the mean Ct value of the controls. C) RT-PCR results obtained with DA926692ex2anewF and DA926692ex2anewR (Table 1), showing a band of 173 bp only in the patient's bone marrow (lane 1) and normal genomic DNA (lane 8). Lanes 2-5 correspond to four control childhood T-ALL bone marrow. Lanes 6, 7 and 9 are normal bone marrow, normal peripheral blood, and blank, respectively. M: 2-Log DNA Ladder (New England Biolabs, Milan, Italy). D) Control RT-PCR with ACTB primers to check the RNA quality, excluding contamination of genomic DNA in the patient's bone marrow RNA.

The same approach was used for DA926692. A primer set specific for exon 1, upstream to the breakpoint, revealed no statistically significant difference in expression level compared to controls (Fig, 2B). Interestingly, a primer pair designed in exon 2 (Table 1), downstream to the breakpoint, detected expression only in the t(2;11) case. RT-PCR with the same primer pair revealed a band of 173 pb only in the patient's BM and in the genomic DNA sample, but neither in the T-ALL controls, nor in normal BM or PB (Fig. 2C). These results were confirmed by nested RT-PCR with the primer pair DA926692 ex2a, further validated by the sequencing of PCR products (data not shown). Purity of all RNA samples was tested using ACTB primers in PCR experiments (Fig. 2D).

Next, we investigated the expression pattern of 3'DA926692 by RQ-PCR in 21 adult tissues. The results showed the occurrence of the transcript in 6 of 23 examined tissues (Fig. 3) [normal BM and PB were already shown to be negative (Fig. 2C)].
Figure 3

Tissue expression pattern of EST DA926692: DA926692 expression analysis was performed using cDNA multiple tissue (Ambion, Milan, Italy) First Choice Total RNA Survey Panel (Catalog No. AM6000) (adipose, bladder, brain, cervix, esophagus, heart, kidney, liver, lung, ovary, placenta, prostate, skeletal muscle, small intestine, spleen, testes, thymus, thyroid, trachea), according to the manufacturer's instructions. We have also tested a pool of tonsil cDNA extracted from three normal individuals. The primer combination used was DA926692ex2anew (F+R). The results, evaluated by RQ-PCR, showed positivity of spleen, ovary, placenta, thyroid, lung, and colon. Compared with the reference ACTB gene expression levels (data not shown), the overall DA926692 expression in the positive tissues was found to be relatively low (2-ΔCt ≤ 1.8 × 10-4). The strongest expression was seen in the colon.

Notably, in silico translation of the sequence corresponding to the 173 bp PCR product showed that it contained a high density of stop codons resulting in very short ORFs.

We hypothesized that this ncRNA could represent a precursor of an miRNA, but the miRNA prediction table produced by miRRim http://mirrim.ncrna.org/TableS1.html and a sequence similarity search at miRBase http://microrna.sanger.ac.uk/sequences/search.shtml showed no significant matches (data not shown). Similarly, miRNA predictions by ProMiR II http://cbit.snu.ac.kr/~ProMiR2/ and miR-abela http://www.mirz.unibas.ch/ did not retrieve any positive results (data not shown).

Finally, we used the Gene Prediction tracks of the UCSC Genome Browser to discover if DA926692 might be part of a more complex predicted gene. Notably, the N-SCAN PASA-EST track showed that DA926692 and the EST CD110063, located in a double position both proximally (chr2:97,362,909–97,379,287) and distally (chr2:97,391,882–97,408,261) to DA926692 (Fig. 1E), may be parts of the predicted gene chr2.98.005.a (data not shown).

To verify this hypothesis, we checked for chr2.98.005.a gene expression using the primer combination DA926692ex2anewF+CD110063-R in the patient's BM cDNA. No PCR products were recovered.

In conclusion, we describe a t(2;11) translocation in T-ALL not resulting in any HPS5/DA926692 chimeric transcript. The impact on cancer causation of a category of "unproductive" translocations, such as ETV6 gene fusions, remains unclear [5]. In such cases, the pathogenetic outcome does not seem to coincide with the formation of a chimeric protein, but perhaps with the production of a truncated form of original proteins (loss of function), or the deregulation of flanking genes.

Here, the only observed gene expression change consisted in the ectopic expression of the 3' portion of DA926692 in the patient's BM (Fig. 2C). One hypothesis is that the juxtaposition, at a distance of only 196 nt, of this genomic segment to the CpG island located upstream to both HPS5 and GTF2H1 (chr11:18,300,202–18,300,814) could have activated its expression in the BM cells of the patient.

DA926692 was isolated from a small intestine cDNA library, described as similar to Ig kappa chain V-I region HK103 precursor http://www-bimas.cit.nih.gov/cgi-bin/cards/carddisp.pl?gene=LOC643543%26;search=DA926692x%26;suff=txt, but no known function has yet been reported. Its expression in some human adult tissues (Fig. 3) may suggest a potential function of this transcript in the positive samples.

As its function is unclear, it is difficult to speculate on a possible role of this short ncRNA in T-ALL tumorigenesis. As the bioinformatic analysis excluded the possibility that it could behave as a pre-miRNA, we could speculate that this ncRNA may belong to the class of small RNA (20–300 nt), commonly found as transcriptional and translational regulators [9, 10]. A variety of complex cellular mechanisms such as gene transcription, chromatin structure dynamics, and others have already been connected to their function [10]. Furthermore, changes in expression levels of ncRNAs have been associated with different types of cancer [9].

In this context, we could speculate that the ectopic expression of the 3' portion of DA926692 in chilhood T-ALL could have a pathogenetic role, even if of still unclear significance. It is presently unknown, however, if the described rearrangement represents a primary or a secondary genetic aberration at disease onset. Further studies on similar cases may be extremely important to confirm this new impact of chromosomal translocation, i.e. activation of ncRNA in tumors.

Notes

Abbreviations

(T-ALL): 

T-cell Acute Lymphoblastic Leukemia

(TCR): 

T-Cell Receptor

(CT): 

Computed Tomography

(BM): 

Bone Marrow

(PB): 

Peripheral Blood

(FISH): 

Fluorescence In Situ Hybridization

(BAC): 

Bacterial Artificial Chromosome

(HPS5): 

Hermansky-Pudlak syndrome 5 isoform b

(GTF2H1): 

general transcription factor IIH, polypeptide 1

(nt): 

nucleotide

(RQ-PCR): 

Real-Time Quantitative PCR

(ANKRD36): 

ankyrin repeat domain 36

(FAHD2B): 

fumarylacetoacetate hydrolase domain containing

(KIAA1641): 

hypothetical protein LOC57730

(ZAP70): 

zeta-chain associated protein kinase 70 KDa

(ORFs): 

Open Reading Frames

(miRNAs): 

microRNAs

(ncRNA): 

non-coding RNA.

Declarations

Acknowledgements

This work has been supported by AIRC (Associazione Italiana per la Ricerca sul Cancro), the MIUR (Ministero dell'Istruzione, dell'Università e della Ricerca), and Fondazione Città della Speranza. The authors thank Dr. A. Pico, Dr. A. Tornesello, and Dr. E. Giarin for their contribution to the study, and Prof. Roscoe Stanyon for language revision of the manuscript.

Authors’ Affiliations

(1)
Department of Genetics and Microbiology, University of Bari
(2)
Department of Hematology, University of Bari
(3)
Laboratorio di Genetica Medica, AUSL LE
(4)
Oncoematologia Pediatrica, AUSL LE
(5)
Department of Clinical Genetics, University Hospital
(6)
Department of Pediatrics, Laboratory of Pediatric Onco-Hematology, University of Padova

References

  1. Mitelman F, Johansson B, Mertens F: The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer. 2007, 7: 233-245. 10.1038/nrc2091View ArticlePubMedGoogle Scholar
  2. van Dyck F, Declercq J, Braem CV, van de Ven WJ: PLAG1, the prototype of the PLAG gene family: versatility in tumour development (review). Int J Oncol. 2007, 30: 765-774.PubMedGoogle Scholar
  3. Storlazzi CT, Albano F, Lo Cunsolo C, Doglioni C, Guastadisegni MC, Impera L, Lonoce A, Funes S, Macri E, Iuzzolino P: Upregulation of the SOX5 by promoter swapping with the P2RY8 gene in primary splenic follicular lymphoma. Leukemia. 2007, 21: 2221-2225. 10.1038/sj.leu.2404784View ArticlePubMedGoogle Scholar
  4. Anglesio MS, Evdokimova V, Melnyk N, Zhang L, Fernandez CV, Grundy PE, Leach S, Marra MA, Brooks-Wilson AR, Penninger J, Sorensen PH: Differential expression of a novel ankyrin containing E3 ubiquitin-protein ligase, Hace1, in sporadic Wilms' tumor versus normal kidney. Hum Mol Genet. 2004, 13: 2061-2074. 10.1093/hmg/ddh215View ArticlePubMedGoogle Scholar
  5. Panagopoulos I, Strombeck B, Isaksson M, Heldrup J, Olofsson T, Johansson B: Fusion of ETV6 with an intronic sequence of the BAZ2A gene in a paediatric pre-B acute lymphoblastic leukaemia with a cryptic chromosome 12 rearrangement. Br J Haematol. 2006, 133: 270-275. 10.1111/j.1365-2141.2006.06020.xView ArticlePubMedGoogle Scholar
  6. Graux C, Cools J, Michaux L, Vandenberghe P, Hagemeijer A: Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast. Leukemia. 2006, 20: 1496-1510. 10.1038/sj.leu.2404302View ArticlePubMedGoogle Scholar
  7. Flohr T, Schrauder A, Cazzaniga G, Panzer-Grumayer R, Velden van der V, Fischer S, Stanulla M, Basso G, Niggli FK, Schafer BW: Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia. 2008, 22: 771-782. 10.1038/leu.2008.5View ArticlePubMedGoogle Scholar
  8. Mitelman F: ISCN. An international system for human cytogenetic nomenclature. 1995, Basel, Switzerland: Karger.Google Scholar
  9. Costa FF: Non-coding RNAs: lost in translation?. Gene. 2007, 386: 1-10. 10.1016/j.gene.2006.09.028View ArticlePubMedGoogle Scholar
  10. Mattick JS, Makunin IV: Non-coding RNA. Hum Mol Genet. 2006, 15 (Spec No 1): R17-29. 10.1093/hmg/ddl046View ArticlePubMedGoogle Scholar

Copyright

© Corsignano et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement